abstract |
Provided herein are methods of administering a 5,5-fused heteroarylene hepatitis C virus inhibitor compound or an isotopic variant thereof, or a pharmaceutically acceptable salt or solvate thereof; for treating or preventing hepatitis C virus infection in a subject. |